Related Experiment Videos

Type V hyperlipoproteinaemia re-visted: findings in a sydney population

Australian and New Zealand Journal of Medicine
|June 1, 1975
PubMed

Insights

Type V hyperlipoproteinaemia, a rare lipid disorder, often affects males and is linked to obesity and diabetes. Treatment responses vary, with alcohol withdrawal and dietary changes showing promise.

Area of Science:

  • Metabolic Disorders
  • Lipid Metabolism
  • Clinical Biochemistry

Background:

  • Type V hyperlipoproteinaemia is a rare genetic disorder characterized by elevated levels of both cholesterol and triglycerides.
  • This condition is associated with a high incidence of comorbidities including obesity, vascular disease, acute abdominal pain, gout, diabetes mellitus, and alcoholism.

Purpose of the Study:

  • To review the clinical and biochemical features of eleven patients diagnosed with Type V hyperlipoproteinaemia.
  • To investigate the associations between Type V hyperlipoproteinaemia and common comorbidities.
  • To evaluate the variable responses to different treatment modalities.

Main Methods:

  • Retrospective review of clinical and biochemical data from eleven male patients with Type V hyperlipoproteinaemia.
  • Analysis of plasma lipid profiles, including cholesterol and triglyceride levels.
  • Assessment of treatment responses to alcohol withdrawal, diabetes management, and carbohydrate-calorie restriction.

Main Results:

  • All studied patients were male, with significant co-occurrence of obesity, vascular disease, acute abdominal pain, gout, diabetes mellitus, and alcoholism.
  • Plasma cholesterol ranged from 212 to 1512 mg/100ml and triglycerides from 708 to 7670 mg/100 ml.
  • Lipaemia led to hyponatraemia and interfered with glucose and amylase measurements. Chylomicronaemia and hyperprebetalipoproteinaemia were associated with reduced beta and alpha lipoproteins, which were cholesterol-depleted relative to triglycerides.

Conclusions:

  • Type V hyperlipoproteinaemia presents with a distinct set of clinical and biochemical abnormalities and is frequently associated with metabolic comorbidities.
  • Treatment outcomes are variable, with alcohol withdrawal and specific diabetes management strategies showing potential for lipid improvement.
  • Further research is needed to clarify the optimal therapeutic approaches and understand the contributions of different interventions.

Related Concept Videos